Jing Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Lu has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Xiaoshuo Dai
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China
15 shared publicationsZiming Dong
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Zhengzhou University, Zhengzhou, Henan Province 450052, PR China; Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China
14 shared publicationsWei Chen
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China
13 shared publicationsKangdong Liu
Department of Pathophysiology, School of Basic Medical Sciences
12 shared publicationsJimin Zhao
11 shared publicationsXiaoxuan Duan
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China
10 shared publications
Latest Publications
- 7 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105259
Fatty acid metabolic reprogramming in gastrointestinal tumor microenvironment: Emerging mechanisms and therapeutic opportunities
- 7 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105259
Fatty acid metabolic reprogramming in gastrointestinal tumor microenvironment: Emerging mechanisms and therapeutic opportunities
- 20 February 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189564
Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies
- 20 February 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (2) , 189564
Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies
- 31 October 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (12) , 7423-7433
Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer Therapy
Monoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials. One of the lessons learned from these practices is that for effective anticancer treatment, further modification of drug-like properties, particularly serum half-life, is crucial. In this project, we developed a humanized anti-B7-H3 antibody of strong affinity (KD = 0.545 nM) through a combined mouse immunization and phage display selection, followed by complementary-determining region grafting. Based on this work, we endeavored to further improve its half-life through engineering its constant fragment (Fc) by substituting two key amino acids, M428L and N434S. The resulting antibody, namely, A172-Hu3-LS, exhibited improved affinity to the neonatal Fc receptor (FcRn) while retaining its cytotoxicity against ESCC cells. Further investigation in the human FcRn transgenic mice demonstrated that this Fc-optimized antibody had a prolonged in vivo half-life (7.9 days) and potent antitumor activity. The significance of this Fc-engineering method lies in its ability to enhance the pharmacokinetic properties of therapeutic antibodies and holds potential for optimizing other therapeutic antibodies, paving the way for more effective and durable cancer treatments. While ESCC was the focus of this study, the broad expression of B7-H3 in various cancers suggests that this work may contribute to the treatment of other B7-H3-expressing tumors.
- 31 October 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (12) , 7423-7433
Fc-Engineered B7-H3 Antibody with Prolonged Serum Half-Life for Enhanced Cancer Therapy
Monoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials. One of the lessons learned from these practices is that for effective anticancer treatment, further modification of drug-like properties, particularly serum half-life, is crucial. In this project, we developed a humanized anti-B7-H3 antibody of strong affinity (KD = 0.545 nM) through a combined mouse immunization and phage display selection, followed by complementary-determining region grafting. Based on this work, we endeavored to further improve its half-life through engineering its constant fragment (Fc) by substituting two key amino acids, M428L and N434S. The resulting antibody, namely, A172-Hu3-LS, exhibited improved affinity to the neonatal Fc receptor (FcRn) while retaining its cytotoxicity against ESCC cells. Further investigation in the human FcRn transgenic mice demonstrated that this Fc-optimized antibody had a prolonged in vivo half-life (7.9 days) and potent antitumor activity. The significance of this Fc-engineering method lies in its ability to enhance the pharmacokinetic properties of therapeutic antibodies and holds potential for optimizing other therapeutic antibodies, paving the way for more effective and durable cancer treatments. While ESCC was the focus of this study, the broad expression of B7-H3 in various cancers suggests that this work may contribute to the treatment of other B7-H3-expressing tumors.
- 15 September 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 275, 156233
Sphingolipid metabolism patterns reveal distinct prognostic and immune landscapes in head and neck squamous cell carcinoma
- 15 September 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 275, 156233
Sphingolipid metabolism patterns reveal distinct prognostic and immune landscapes in head and neck squamous cell carcinoma
- 11 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115042
JAK3/STAT5A-dependent IL-8 regulation drives ESCC angiogenesis and is suppressed by dihydroartemisinin
- 11 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115042
JAK3/STAT5A-dependent IL-8 regulation drives ESCC angiogenesis and is suppressed by dihydroartemisinin
- 13 April 2025
- Published by Wiley in Molecular Carcinogenesis
- Vol. 64 (7) , 1168-1181
SRPK1 Activation Facilitates Gli3S664 Phosphorylation and Promotes Metastasis in Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) stands out as one of the most malignant digestive tumors, with its prognosis marred by frequent metastasis and recurrence. However, the mechanism behind ESCC metastasis remains elusive, impeding therapeutic advancements. SRPK1 emerges as an independent prognostic marker for ESCC patients. Our research illuminates the consequential role of SRPK1, where its genetic knockout led to decreased levels of transcription factors Snail and Slug, concomitant with an enhanced expression of the cell‐to‐cell adhesion protein E‐cadherin. Conversely, reintroducing an overexpression of SRPK1 reversed the effects, highlighting its essential role in ESCC metastasis. Through bioinformatics analysis, we identified a correlation between SRPK1 and Gli3. Furthermore, increased levels of Gli3 and its phosphorylated form, p‐Gli3S664, were detected in ESCC tissues, which are implicated in promoting ESCC metastasis. Notably, our research confirmed that SRPK1 promotes migration, invasion, and epithelial−mesenchymal transition (EMT) of ESCC cells through phosphorylates Gli3 at ser 664. Additional investigations reveal that dihydroartemisinin (DHA) effectively impedes ESCC cell metastasis by suppressing SRPK1‐mediated phosphorylation of Gli3S664 both in vitro and in vivo. Consequently, our study underscores the pivotal role of the SRPK1‐p‐Gli3S664 axis in ESCC metastasis and suggests DHA as a promising candidate for preventing ESCC metastasis by targeting this axis.
- 13 April 2025
- Published by Wiley in Molecular Carcinogenesis
- Vol. 64 (7) , 1168-1181
SRPK1 Activation Facilitates Gli3S664 Phosphorylation and Promotes Metastasis in Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) stands out as one of the most malignant digestive tumors, with its prognosis marred by frequent metastasis and recurrence. However, the mechanism behind ESCC metastasis remains elusive, impeding therapeutic advancements. SRPK1 emerges as an independent prognostic marker for ESCC patients. Our research illuminates the consequential role of SRPK1, where its genetic knockout led to decreased levels of transcription factors Snail and Slug, concomitant with an enhanced expression of the cell‐to‐cell adhesion protein E‐cadherin. Conversely, reintroducing an overexpression of SRPK1 reversed the effects, highlighting its essential role in ESCC metastasis. Through bioinformatics analysis, we identified a correlation between SRPK1 and Gli3. Furthermore, increased levels of Gli3 and its phosphorylated form, p‐Gli3S664, were detected in ESCC tissues, which are implicated in promoting ESCC metastasis. Notably, our research confirmed that SRPK1 promotes migration, invasion, and epithelial−mesenchymal transition (EMT) of ESCC cells through phosphorylates Gli3 at ser 664. Additional investigations reveal that dihydroartemisinin (DHA) effectively impedes ESCC cell metastasis by suppressing SRPK1‐mediated phosphorylation of Gli3S664 both in vitro and in vivo. Consequently, our study underscores the pivotal role of the SRPK1‐p‐Gli3S664 axis in ESCC metastasis and suggests DHA as a promising candidate for preventing ESCC metastasis by targeting this axis.
- 19 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 306 (Pt 1) , 141249
Selection and identification of DNA aptamer binding VDAC1 for tumor tissue imaging and targeted drug delivery
- 19 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 306 (Pt 1) , 141249
Selection and identification of DNA aptamer binding VDAC1 for tumor tissue imaging and targeted drug delivery
- 2 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 1) , 113257
KNTC1 functions as a potential biomarker and oncogene regulating proliferation, migration and apoptosis in gastric cancer
- 2 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 1) , 113257
KNTC1 functions as a potential biomarker and oncogene regulating proliferation, migration and apoptosis in gastric cancer
- 23 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 131, 111846
Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions
- 23 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 131, 111846
Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions